Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), an emerging growth company incorporated in Florida, filed this Form 8-K on July 6, 2026. The filing discloses positive preclinical study results for SKNY-1, an oral drug candidate in development for obesity and addiction-related disorders.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding scientific progress and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is the advancement of the SKNY-1 development program. Preclinical studies of the optimized oral formulation demonstrated:
- Favorable oral bioavailability and reproducible systemic exposure.
- Robust brain penetration and substantial liver exposure.
- Pharmacokinetics supporting potential once-daily oral dosing.
These findings complement previously reported efficacy data showing reductions in body weight, preservation of lean mass, and attenuation of compulsive feeding and nicotine-seeking behaviors without anxiety-related effects.
Outlook and Management Commentary
Management believes these pharmacokinetic findings strengthen the development profile of SKNY-1 by confirming that the oral formulation delivers meaningful exposure to pharmacologically relevant tissues. The filing does not provide specific financial guidance, risk factors, or contingencies beyond the standard disclaimer that the information is furnished and not "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed study parameters.
- Review the Company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K contains no financial data.
- Confirm the timeline for transitioning SKNY-1 from preclinical studies to clinical trials.
- Monitor for any updates on the regulatory pathway for SKNY-1 given its cannabinoid receptor activity.